Kaye Scholer Advises Sandoz in Commercialization Agreement with Anacor Pharmaceuticals
July 21, 2014
Kaye Scholer advised Sandoz Inc., the generic pharmaceuticals division of Novartis, in an agreement with Anacor Pharmaceuticals, Inc. granting Sandoz exclusive rights to commercialize Anacor’s drug KERYDINTM (tavaborole) topical solution, 5% in the United States, through its branded dermatology business, PharmaDerm. For more information, please see the Sandoz press release announcing the transaction here.
The Kaye Scholer team advising Sandoz in this matter includes Partner Andres Liivak and Associate Viktoriya Karshenboyem. Intellectual Property Partner David Barr and Associate Philip Smithback also contributed to the team's efforts in this transaction.